Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1984 May;81(9):2898–2901. doi: 10.1073/pnas.81.9.2898

Multiple opioid receptors in endotoxic shock: evidence for delta involvement and mu-delta interactions in vivo.

R D'Amato, J W Holaday
PMCID: PMC345180  PMID: 6326151

Abstract

The use of selective delta and mu opioid antagonists has provided evidence that delta opioid receptors within the brain mediate the endogenous opioid component of endotoxic shock hypotension. The selectivity of these delta and mu antagonists was demonstrated by their differing effects upon morphine analgesia and endotoxic hypotension. The mu antagonist beta-funaltrexamine, at doses that antagonized morphine analgesia, failed to alter shock, whereas the delta antagonist M 154,129: [N,N-bisallyl-Tyr-Gly-Gly-psi-(CH2S)-Phe-Leu-OH] (ICI) reversed shock at doses that failed to block morphine analgesia. Therefore, selective delta antagonists may have therapeutic value in reversing circulatory shock without altering the analgesic actions of endogenous or exogenous opioids. Additional data revealed that prior occupancy of mu binding sites by irreversible opioid antagonists may allosterically attenuate the actions of antagonists with selectivity for delta binding sites. For endogenous opioid systems, this observation provides an opportunity to link in vivo physiological responses with receptor-level biochemical interactions.

Full text

PDF
2898

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amir S. Opiate antagonists improve survival in anaphylactic shock. Eur J Pharmacol. 1982 May 7;80(1):161–162. doi: 10.1016/0014-2999(82)90194-7. [DOI] [PubMed] [Google Scholar]
  2. Bowen W. D., Gentleman S., Herkenham M., Pert C. B. Interconverting mu and delta forms of the opiate receptor in rat striatal patches. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4818–4822. doi: 10.1073/pnas.78.8.4818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Curtis M. T., Lefer A. M. Actions of opiate antagonists with selective receptor interactions in hemorrhagic shock. Circ Shock. 1983;10(2):131–145. [PubMed] [Google Scholar]
  4. Curtis M. T., Lefer A. M. Beneficial action of a new opiate antagonist (Win 44,441-3) in hemorrhagic shock. Eur J Pharmacol. 1982 Mar 12;78(3):307–313. doi: 10.1016/0014-2999(82)90032-2. [DOI] [PubMed] [Google Scholar]
  5. Faden A. I., Jacobs T. P., Holaday J. W. Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. N Engl J Med. 1981 Oct 29;305(18):1063–1067. doi: 10.1056/NEJM198110293051806. [DOI] [PubMed] [Google Scholar]
  6. Gurll N. J., Reynolds D. G., Vargish T., Lechner R. Naltrexone improves survival rate and cardiovascular function in canine hemorrhagic shock. J Pharmacol Exp Ther. 1982 Mar;220(3):625–628. [PubMed] [Google Scholar]
  7. Henry J. L. Circulating opioids: possible physiological roles in central nervous function. Neurosci Biobehav Rev. 1982 Fall;6(3):229–245. doi: 10.1016/0149-7634(82)90040-9. [DOI] [PubMed] [Google Scholar]
  8. Holaday J. W. Cardiorespiratory effects of mu and delta opiate agonists following third or fourth ventricular injections. Peptides. 1982 Nov-Dec;3(6):1023–1029. doi: 10.1016/0196-9781(82)90073-0. [DOI] [PubMed] [Google Scholar]
  9. Holaday J. W. Cardiovascular effects of endogenous opiate systems. Annu Rev Pharmacol Toxicol. 1983;23:541–594. doi: 10.1146/annurev.pa.23.040183.002545. [DOI] [PubMed] [Google Scholar]
  10. Holaday J. W., D'Amato R. J., Faden A. I. Thyrotropin-releasing hormone improves cardiovascular function in experimental endotoxic and hemorrhagic shock. Science. 1981 Jul 10;213(4504):216–218. doi: 10.1126/science.6787704. [DOI] [PubMed] [Google Scholar]
  11. Holaday J. W., D'Amato R. J. Multiple opioid receptors: evidence for mu-delta binding site interactions in endotoxic shock. Life Sci. 1983;33 (Suppl 1):703–706. doi: 10.1016/0024-3205(83)90599-4. [DOI] [PubMed] [Google Scholar]
  12. Holaday J. W., Faden A. I. Naloxone acts at central opiate receptors to reverse hypotension, hypothermia and hypoventilation in spinal shock. Brain Res. 1980 May 5;189(1):295–300. doi: 10.1016/0006-8993(80)90032-3. [DOI] [PubMed] [Google Scholar]
  13. Holaday J. W., Faden A. I. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature. 1978 Oct 5;275(5679):450–451. doi: 10.1038/275450a0. [DOI] [PubMed] [Google Scholar]
  14. Holaday J. W., Pasternak G. W., D'Amato R. J., Ruvio B. A., Faden A. I. Naloxazone lacks therapeutic effects in endotoxic shock yet blocks the effects of naloxone. Eur J Pharmacol. 1983 May 6;89(3-4):293–296. doi: 10.1016/0014-2999(83)90509-5. [DOI] [PubMed] [Google Scholar]
  15. Iwamoto E. T., Martin W. R. Multiple opioid receptors. Med Res Rev. 1981 Winter;1(4):411–440. doi: 10.1002/med.2610010406. [DOI] [PubMed] [Google Scholar]
  16. Krieger D. T. Endorphins and enkephalins. Dis Mon. 1982 Jul;28(10):1–53. doi: 10.1016/0011-5029(82)90633-2. [DOI] [PubMed] [Google Scholar]
  17. Lee N. M., Smith A. P. A protein-lipid model of the opiate receptor. Life Sci. 1980 May 5;26(18):1459–1464. doi: 10.1016/0024-3205(80)90266-0. [DOI] [PubMed] [Google Scholar]
  18. Li C. H. beta-Endorphin. Cell. 1982 Dec;31(3 Pt 2):504–505. doi: 10.1016/0092-8674(82)90305-1. [DOI] [PubMed] [Google Scholar]
  19. Peters W. P., Johnson M. W., Friedman P. A., Mitch W. E. Pressor effect of naloxone in septic shock. Lancet. 1981 Mar 7;1(8219):529–532. doi: 10.1016/s0140-6736(81)92865-8. [DOI] [PubMed] [Google Scholar]
  20. Shaw J. S., Miller L., Turnbull M. J., Gormley J. J., Morley J. S. Selective antagonists at the opiate delta-receptor. Life Sci. 1982 Sep 20;31(12-13):1259–1262. doi: 10.1016/0024-3205(82)90356-3. [DOI] [PubMed] [Google Scholar]
  21. Takemori A. E., Larson D. L., Portoghese P. S. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur J Pharmacol. 1981 Apr 9;70(4):445–451. doi: 10.1016/0014-2999(81)90355-1. [DOI] [PubMed] [Google Scholar]
  22. Terenius L. Endogenous peptides and analgesia. Annu Rev Pharmacol Toxicol. 1978;18:189–204. doi: 10.1146/annurev.pa.18.040178.001201. [DOI] [PubMed] [Google Scholar]
  23. Tiengo M. Naloxone in irreversible shock. Lancet. 1980 Sep 27;2(8196):690–690. doi: 10.1016/s0140-6736(80)92723-3. [DOI] [PubMed] [Google Scholar]
  24. Vaught J. L., Rothman R. B., Westfall T. C. Mu and delta receptors: their role in analgesia in the differential effects of opioid peptides on analgesia. Life Sci. 1982 Apr 26;30(17):1443–1455. doi: 10.1016/0024-3205(82)90558-6. [DOI] [PubMed] [Google Scholar]
  25. Ward S. J., Portoghese P. S., Takemori A. E. Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther. 1982 Mar;220(3):494–498. [PubMed] [Google Scholar]
  26. Zukin R. S., Zukin S. R. Multiple opiate receptors: emerging concepts. Life Sci. 1981 Dec 28;29(26):2681–2690. doi: 10.1016/0024-3205(81)90527-0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES